16Jun
Diligence Clauses and the Management of Uncertainty in Life Sciences Agreements
In times of uncertainty and disruption, setting expectations for performance with business partners and contractual counterparties can be more complicated than ever. Companies that develop drugs, biologics and medical devices have considerable...
By:
Skadden, Arps, Slate, Meagher & Flom LLP
Related
It was a pleasure to see so many of our clients and friends at our annual Labor & Employment Hot Top...
Read More >
Is My New Hire an Employee or a Contractor? Key Factors for Startups to Consider Employee or contra...
Read More >
On August 28, 2019, the amendment to Transitory XI of the social security contribution towards Disab...
Read More >
Even as they make their investment, private equity investors are focused on their exit. A standard f...
Read More >
On September 24, 2019, the U.S. Department of Labor (“DOL”) issued its delayed Rule increasing the...
Read More >
In the first quarter of 2020, no sector was able to avoid the declining interest in M&A caused b...
Read More >